HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Impaired glucose tolerance in obese — Clinical Guidelines

Overview

Obesity is a complex condition associated with numerous comorbidities, including type 2 diabetes 1. Impaired glucose tolerance is a metabolic state that increases the risk of developing type 2 diabetes 1.

Diagnosis

No diagnostic criteria or recommended tests for impaired glucose tolerance in obese individuals were found in the provided abstracts.

Management

Pharmacological management of obesity can improve outcomes and decrease the risk of obesity-related complications 3. Pharmacotherapy is recommended in addition to lifestyle intervention for adults with overweight and obesity (body mass index ≥30 kg/m2) who have an inadequate response to lifestyle interventions alone 3. Multiple effective and safe treatment options are available for long-term pharmacological therapy 3.

Special Populations

No information on special populations was found in the provided abstracts.

Key Recommendations

Pharmacotherapy should be used in addition to lifestyle intervention in adults with overweight and obesity (body mass index ≥30 kg/m2) 3. (Evidence: Strong)

In adults with overweight and obesity who have an inadequate response to lifestyle interventions alone, long-term pharmacological therapy is recommended, with multiple effective and safe treatment options available 3. (Evidence: Strong)

Obesity likely increases the risk of asthma, but evidence for associations with other allergic diseases is limited 2. (Evidence: Moderate)

References

1 Hellmann RLMV, Sande-Lee SV, Melo ME, Messias ACNV, Maia IWA, Lunardi MC et al.. Care of patients with obesity in the Emergency Department: a joint position statement from the Brazilian Association of Emergency Medicine (ABRAMEDE) and the Brazilian Association for the Study of Obesity and Metabolic Syndrome (ABESO). Archives of endocrinology and metabolism 2025. link 2 Kuniyoshi Y, Tsujimoto Y, Banno M, Taito S, Ariie T, Kimoto T. Association of obesity or metabolic syndrome with various allergic diseases: An overview of reviews. Obesity reviews : an official journal of the International Association for the Study of Obesity 2025. link 3 Grunvald E, Shah R, Hernaez R, Chandar AK, Pickett-Blakely O, Teigen LM et al.. AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity. Gastroenterology 2022. link

Impaired glucose tolerance in obese